Safety and Efficacy of Vesemnogene lantuparvovec, an AAV-based Gene therapy for Spinal Muscular Atrophy in Children Less Than 24 Months of Age in Low-Middle Income Countries. First interim report as of April 2025.
Lock Hock Ngu, Qingling Mo, Shiqi Li, Teck Hock Toh, Jia Ni Lee, Kok Chong Lim, Edi Setiawan Tehuteru, Rahmi Lestari, Chinnuwat Sanguansermsri, Hany Abueita, Samson Gwer, Li Li, Zhuowei Wang, Salman Kirmani, Julia X Chen, Yilia Y. Cai, Nanette N. Zheng, Yanqing Li, Qian Yang, Yanqiong Tang, Yeqing Li, Jason Z. Ye, Silk J. Shi, Jack F. Hong, Cole K. Zheng, Amy Y. Chen, Sanbin Wang, Teck Onn Lim, Bruce T. Lahn, Austin T. Gao
medRxiv 2025.04.13.25325764; doi: https://doi.org/10.1101/2025.04.13.25325764